TECH: Bio-Techne Corp Price to Sales

Symbol and logo of brand Bio-Techne Corp (TECH)

Bio-Techne Corporation (TECH) generates revenue from the sale of protein reagents and diagnostic systems. P/S volatility confirms the business valuation trend, where the 9.30 metric determines this level. A stable staff of specialized engineers eliminates labor shortages. The resilience of its market position is ensured by unique antibodies and high customer switching costs for alternative tests, which neutralizes competitive pressure.

TECH (Bio-Techne) P/S Multiple history from 07/04/2022 to 11/13/2026

Analytical breakdowns for Techne Corporation (TECH)

- market price and analyst price targets:
Stock Quotes bio-techne.com|TECH - Analyst Consensus Forecast
- market capitalization information:
Market Value Techne Corporation|TECH - Enterprise Value
- shareholders' equity book value data:
Equity per Share Bio-Techne|TECH - Book Capitalization|Market Capitalization to Book Value bio-techne.com|TECH - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Bio-Techne Corporation|TECH - Long-Term Debt to Capital|Short-Term Debt to Capital Bio-Techne Inc.|TECH - Company Debts|Debt to Book Capitalization Ratio Techne Corporation|TECH - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Bio-Techne|Immediate Liquidity bio-techne.com
- net income and valuation multiples indicators:
TECH - Company Net Income|Projected Net Profit Bio-Techne Corporation|TECH - Price to Earnings Ratio|Forward P/E Multiple Bio-Techne Corp|TECH - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Techne Corporation|TECH - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Bio-Techne|TECH - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months bio-techne.com|TECH - Earnings growth in current year|Expected net earnings per share growth next year Bio-Techne Corporation
- issuer revenue and sales details:
TECH - Company Revenue|Company Revenue Forecast bio-techne.com|TECH - Market Cap to Revenue|Price to Expected Revenue Ratio Techne Corporation
Fundamental company analysis:bio-techne.com TECH
Original product of Techne Corporation

The P/S ratio determines the market value of one dollar of revenue, allowing for an assessment of the extent to which a business is overvalued or undervalued relative to its operating sales. By analyzing this price-to-sales valuation on GURU.Markets, an investor can see how the market capitalizes the technological leadership of Bio-Techne Corporation (TECH) in the field of cell therapy and its strategic alliances with global pharma behemoths.

Who Bio-Techne Corporation competes with

Market Cap to Revenue abbott.com ABT|P/S Multiple TMO (Thermo Fisher)|GE HealthCare Technologies Inc. (GEHC) - Price to Sales|Mettler-Toledo International Inc. - P/S Multiple|WAT (Waters Technologies) - Market Cap to Revenue Ratio|BRKR: P/S Multiple|AZTA - Price-to-Revenue Coefficient|VREX (Varex Imaging Corporation) - P/S Multiple|Market Cap to Revenue Semler Scientific Inc (SMLR)|P/S Multiple BFLY|P/S Multiple Mesa Laboratories Corp. (MLAB)|Price-to-Revenue Ratio Quantum-Si QSI|nanox.vision - Price-to-Revenue Ratio|QTRX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio MASS (908 Devices Inc)|CV: P/S Multiple|Price to Sales MaxCyte Inc (MXCT)|Price-to-Revenue Ratio Rapid Micro Biosystems Inc.|SEER - Price-to-Revenue Multiple|Market Cap to Revenue HYPR (Hyperfine)|P/S Multiple FONAR Corp. (FONR)|P/S Multiple DXR (Daxor)|Price-to-Revenue Coefficient spectral-ai.com (MDAI)|VIVS - Price-to-Revenue Ratio|Price-to-Sales Ratio ACON|akoyabio.com (AKYA) - Price-to-Revenue Ratio|Market Cap to Revenue ThermoGenesis Holdings, Inc.|TLIS (Talis Biomedical Corp.) - P/S Multiple|Price to Sales T2 Biosystems Inc TTOO